Trials / Completed
CompletedNCT05227651
AK104 in Neoadjuvant Treatment of Cervical Cancer
Phase II Study on AK104 in Neoadjuvant Treatment of Cervical Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Akeso · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK104 | IV infusion,Specified dose on specified days |
Timeline
- Start date
- 2023-02-10
- Primary completion
- 2024-09-27
- Completion
- 2024-09-27
- First posted
- 2022-02-07
- Last updated
- 2024-11-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05227651. Inclusion in this directory is not an endorsement.